GeneScience Pharmaceuticals Co., Ltd.
GeneScience Pharmaceuticals Co., Ltd., commonly referred to as GeneScience, is a leading biopharmaceutical company headquartered in China (CN). Established in 2002, the company has made significant strides in the biotechnology sector, focusing on the research, development, and production of innovative biopharmaceuticals. With a strong presence in both domestic and international markets, GeneScience excels in areas such as recombinant proteins, monoclonal antibodies, and biosimilars. Their flagship products, including the well-regarded EPO and G-CSF, are distinguished by their high quality and efficacy, setting them apart in a competitive landscape. Recognised for its commitment to advancing healthcare, GeneScience has achieved notable milestones, including numerous regulatory approvals and partnerships that enhance its market position. As a pioneer in the biopharmaceutical industry, GeneScience continues to drive innovation and improve patient outcomes globally.
DitchCarbon Score
How does GeneScience Pharmaceuticals Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
GeneScience Pharmaceuticals Co., Ltd.'s score of 22 is lower than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
GeneScience Pharmaceuticals Co., Ltd., headquartered in China (CN), currently does not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of Changchun High-Tech Industry (Group) Co., Ltd., which may influence its climate-related initiatives and reporting. Despite the lack of direct emissions data, GeneScience Pharmaceuticals is part of a corporate family that may have broader climate commitments. However, there are no documented reduction targets or climate pledges available for GeneScience Pharmaceuticals at this time. The absence of specific initiatives or targets suggests that the company may still be in the early stages of developing its climate strategy. As a subsidiary, GeneScience Pharmaceuticals may benefit from the sustainability practices and targets set by its parent company, Changchun High-Tech Industry (Group) Co., Ltd. However, without explicit data or commitments, it is challenging to assess the company's current impact or future goals regarding carbon emissions and climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 235,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 1,338,000,000 | 0,000,000,000 | 0,000,000,000 |
| Scope 3 | - | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
GeneScience Pharmaceuticals Co., Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
